簡(jiǎn)要描述:RNA結(jié)合蛋白38抗體免 疫 原;KLH conjugated synthetic peptide derived from human RBM38: 51-150/239
產(chǎn)品分類(lèi)
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
RNA結(jié)合蛋白38抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
RNA結(jié)合蛋白38抗體 | RBM38 | GOY-01K1622 |
商品屬性:
英文名稱: RBM38
中文名:RNA結(jié)合蛋白38抗體
別 名;SEB4D; CLL
associated antigen KW 5; CLL-associated antigen KW-5; HSRNASEB; RBM38;
RBM38_HUMAN; RNA binding motif protein 38; RNA binding protein 38; RNA binding
region (RNP1, RRM) containing 1; RNA binding region containing protein 1;
RNA-binding motif protein 38; RNA-binding protein 38; RNA-binding
region-containing protein 1; RNPC1; SEB4; SEB4B; ssDNA binding protein SEB4;
ssDNA-binding protein SEB4.
研究領(lǐng)域;細(xì)胞生物 染色質(zhì)和核信號(hào) 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞 細(xì)胞凋亡 細(xì)胞周期蛋白 表觀遺傳學(xué)
抗體來(lái)源;Rabbit
克隆類(lèi)型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit, )
產(chǎn)品應(yīng)用;ELISA=1:5000-10000
IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;25kDa
細(xì)胞定位;細(xì)胞核 細(xì)胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human RBM38: 51-150/239
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
RNA-binding protein that specifically bind the
3'-UTR of CDKN1A transcripts, leading to maintain the stability of CDKN1A
transcripts, thereby acting as a mediator of the p53/TP53 family to regulate
CDKN1A. CDKN1A is a cyclin-dependent kinase inhibitor transcriptionally
regulated by the p53/TP53 family to induce cell cycle arrest. Isoform 1, but
not isoform 2, has the ability to induce cell cycle arrest in G1 and maintain
the stability of CDKN1A transcripts induced by p53/TP53. Also acts as a mRNA
splicing factor. Specifically regulates the expression of FGFR2-IIIb, an
epithelial cell-specific isoform of FGFR2. Plays a role in myogenic
differentiation. RNA-binding protein that specifically bind the
3'-UTR of CDKN1A transcripts, leading to maintain the stability of CDKN1A
transcripts, thereby acting as a mediator of the p53/TP53 family to regulate
CDKN1A. CDKN1A is a cyclin-dependent kinase inhibitor transcriptionally
regulated by the p53/TP53 family to induce cell cycle arrest. Has the ability
to induce cell cycle arrest in G1 and maintain the stability of CDKN1A
transcripts induced by p53/TP53. Also acts as a mRNA splicing factor.
Specifically regulates the expression of FGFR2-IIIb, an epithelial
cell-specific isoform of FGFR2 (By similarity). Plays a role in myogenic
differentiation. |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專(zhuān)業(yè)的建議。在制備過(guò)程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無(wú)法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類(lèi)型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開(kāi)發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶量身定制的專(zhuān)業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃